Intracystic interferon-alpha in pediatric craniopharyngioma patients
Bibliographic record
Abstract
I read with great interest the paper by John-Paul Kilday et al.1 I congratulate the authors for retrospectively studying 56 patients with craniopharyngiomas from different continents and aged <18 years, a study supported by 2 reputed medical societies in oncology and pediatric neurosurgery, SIOPE and ISPN. However, the results raise some questions and concerns. First, of the 56 enrolled patients treated with intracystic interferon-alpha, 43 had already received other therapies. In our opinion, this affects the overall assessment of these patients. These 43 patients had already failed the primary treatment of choice and were therefore being treated with a second therapeutic modality (interferon-alpha). This calls into question the combined analysis of this group with treatment-naïve patients. In addition, I question why the authors called this treatment modality the “Toronto Protocol,” as this treatment protocol is not substantially different from the protocol that was originally published by Cavalheiro et al2 in 2005 and used to treat patients in São Paulo, Brazil.2,3 The São Paulo team was the first to use and report this treatment, subjecting patients to this new therapeutic modality. They also analyzed and published the cellular changes occurring during and after treatment4 and performed the first multicenter study involving 60 patients.3 I also believe that the authors could have harnessed the collaborative nature of their study and analyzed differences in subgroups of patients with craniopharyngioma that respond differently to distinct treatment modalities. They could also have investigated why the craniopharyngiomas that were not cured with radical surgery, radiotherapy, and/or other intracystic chemotherapy agents also respond poorly to intracystic interferon, as these patients constituted 77% of the total number of patients analyzed. Because some lesions disappeared after only one treatment cycle, the genetic hallmarks of these tumors should have been evaluated. The authors also did not clarify the criteria for new treatment cycles. It was unclear whether they evaluated only the increase in volume or also considered changes in the radiological characteristics of the cystic component. Because previous studies have not determined when interferon treatment should be halted and patients switched to another therapeutic modality, switching hastily may cause false-negative findings of drug efficacy. Because this was a retrospective study involving 21 different centers, the criteria for switching therapy were likely non-uniform. Furthermore, craniopharyngioma surgery after treatment with interferon is no more difficult than after radiotherapy or even after treatment with bleomycin. Following treatment with interferon, the capsule of the craniopharyngioma becomes much more evident, allowing its complete exeresis. A prospective study in treatment-naïve patients, with genomic and proteomic analyses of the fluid removed during the injections, and analyses of radiological modifications before and after interferon treatment, would be very welcome.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.005 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".